In response to continued advances in genomic technology and genetic medicine, the
National Institutes of Health
(NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests. Comprehensive scientific and clinical information about the Oncotype DX
breast cancer test is now incorporated in the GTR database, representing
Genomic Health's
leadership in applying genomic information to make cancer care smarter.
®
"Over the last decade, in partnership with many collaborators, we have demonstrated that the rigorous validation of genomic information can transform cancer treatment," said
Phil Febbo
, M.D., chief medical officer,
Genomic Health
. "As new discoveries about the human genome continue to inspire medical innovations, we are proud to share the breadth of our clinical evidence to showcase how world-class science can be translated into a practice-changing test like Oncotype DX."
Read the news release here:
Source: genomic Health
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More